BioXcel Therapeutics, Inc. Long-Term Debt, Maturity, Year Five
BioXcel Therapeutics, Inc. (BTAI) had Long-Term Debt, Maturity, Year Five of $85.71 million as of 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2023-03-16
- 2022-12-31: Long-Term Debt, Maturity, Year Five $85.71M.
- 2022-09-30: Long-Term Debt, Maturity, Year Five $94.14M.
- 2022-06-30: Long-Term Debt, Maturity, Year Five $70.00M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2022-12-31 | $85.71M 10-K · filed 2023-03-16 |
| 2022-09-30 | $94.14M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $70.00M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |